Biomarkers Evaluated in Children with Community-Acquired Pneumonia
By LabMedica International staff writers Posted on 01 Jun 2020 |

Image: The C-reactive protein (CRP) test was one of the biomarkers evaluated in children with community-acquired pneumonia (Photo courtesy of Healsens Digital Preventive Care).
Community acquired pneumonia (CAP) is one of the most common conditions treated by pediatricians, yet predicting disease severity and prognosis is often difficult at the initial presentation.
Previous studies on adults indicate that the biomarkers C-reactive protein (CRP), white blood cell (WBC) count, absolute neutrophil count (ANC), and procalcitonin may be associated with disease severity. Whether the same was true in children aged three months to 18 years with suspected CAP who presented to the emergency department (ED) has been investigated.
Pediatricians at the Feinberg School of Medicine (Chicago, IL, USA) and their colleagues performed a prospective cohort study of 477 children 3 months to 18 years of age (mean age 5.6 years, 52.6% male, 67% white) with CAP in the emergency department. The primary outcome was disease severity: mild (discharged from the hospital), mild-moderate (hospitalized but not moderate-severe or severe), moderate-severe (e.g., hospitalized with receipt of intravenous fluids, supplemental oxygen, complicated pneumonia), and severe (e.g., intensive care, vasoactive infusions, chest drainage, severe sepsis). Outcomes were examined within the cohort with suspected CAP and in a subset with radiographic CAP.
The scientists reported that there were no statistical differences in median WBC count, CRP level, ANC, or procalcitonin level across four different categories of disease severity. However, when specific outcomes were examined, CRP and procalcitonin levels were higher in those developing complicated pneumonia requiring chest tube placement and sepsis requiring vasoactive medications. Additionally, all biomarkers had high negative predictive values (NPV) in differentiating severe from non-severe disease and may therefore be useful in ruling out severe outcomes.
In analyses adjusted for age, antibiotic use, fever duration, and viral pathogen detection, CRP was associated with moderate-severe disease (odds ratio 1.12). CRP and procalcitonin revealed good discrimination of children with empyema requiring chest drainage (AUC: 0.83) and sepsis with vasoactive infusions (CRP AUC: 0.74; procalcitonin AUC: 0.78), although prevalence of these outcomes was low.
The authors concluded that WBC count, ANC, CRP, and procalcitonin are generally not useful to discriminate non-severe from severe disease in children with CAP, although CRP and procalcitonin may have some utility in predicting the most severe outcomes. The study was published in the May, 2020 issue of the journal Pediatrics.
Related Links:
Feinberg School of Medicine
Previous studies on adults indicate that the biomarkers C-reactive protein (CRP), white blood cell (WBC) count, absolute neutrophil count (ANC), and procalcitonin may be associated with disease severity. Whether the same was true in children aged three months to 18 years with suspected CAP who presented to the emergency department (ED) has been investigated.
Pediatricians at the Feinberg School of Medicine (Chicago, IL, USA) and their colleagues performed a prospective cohort study of 477 children 3 months to 18 years of age (mean age 5.6 years, 52.6% male, 67% white) with CAP in the emergency department. The primary outcome was disease severity: mild (discharged from the hospital), mild-moderate (hospitalized but not moderate-severe or severe), moderate-severe (e.g., hospitalized with receipt of intravenous fluids, supplemental oxygen, complicated pneumonia), and severe (e.g., intensive care, vasoactive infusions, chest drainage, severe sepsis). Outcomes were examined within the cohort with suspected CAP and in a subset with radiographic CAP.
The scientists reported that there were no statistical differences in median WBC count, CRP level, ANC, or procalcitonin level across four different categories of disease severity. However, when specific outcomes were examined, CRP and procalcitonin levels were higher in those developing complicated pneumonia requiring chest tube placement and sepsis requiring vasoactive medications. Additionally, all biomarkers had high negative predictive values (NPV) in differentiating severe from non-severe disease and may therefore be useful in ruling out severe outcomes.
In analyses adjusted for age, antibiotic use, fever duration, and viral pathogen detection, CRP was associated with moderate-severe disease (odds ratio 1.12). CRP and procalcitonin revealed good discrimination of children with empyema requiring chest drainage (AUC: 0.83) and sepsis with vasoactive infusions (CRP AUC: 0.74; procalcitonin AUC: 0.78), although prevalence of these outcomes was low.
The authors concluded that WBC count, ANC, CRP, and procalcitonin are generally not useful to discriminate non-severe from severe disease in children with CAP, although CRP and procalcitonin may have some utility in predicting the most severe outcomes. The study was published in the May, 2020 issue of the journal Pediatrics.
Related Links:
Feinberg School of Medicine
Latest Clinical Chem. News
- Mass Spectrometry Detects Bacteria Without Time-Consuming Isolation and Multiplication
- First Comprehensive Syphilis Test to Definitively Diagnose Active Infection In 10 Minutes
- Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse
- ‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection
- Low-Cost Portable Screening Test to Transform Kidney Disease Detection
- New Method Uses Pulsed Infrared Light to Find Cancer's 'Fingerprints' In Blood Plasma
- Carbon Nanotubes Help Build Highly Accurate Sensors for Continuous Health Monitoring
- Paper-Based Device Boosts HIV Test Accuracy from Dried Blood Samples
- AI-Powered Raman Spectroscopy Method Enables Rapid Drug Detection in Blood
- Novel LC-MS/MS Assay Detects Low Creatinine in Sweat and Saliva
- Biosensing Technology Breakthrough Paves Way for New Methods of Early Disease Detection
- New Saliva Test Rapidly Identifies Paracetamol Overdose
- POC Saliva Testing Device Predicts Heart Failure in 15 Minutes
- Screening Tool Detects Multiple Health Conditions from Single Blood Drop
- Integrated Chemistry and Immunoassay Analyzer with Extensive Assay Menu Offers Flexibility, Scalability and Data Commutability
- Rapid Drug Test to Improve Treatment for Patients Presenting to Hospital
Channels
Clinical Chemistry
view channelMass Spectrometry Detects Bacteria Without Time-Consuming Isolation and Multiplication
Speed and accuracy are essential when diagnosing diseases. Traditionally, diagnosing bacterial infections involves the labor-intensive process of isolating pathogens and cultivating bacterial cultures,... Read more
First Comprehensive Syphilis Test to Definitively Diagnose Active Infection In 10 Minutes
In the United States, syphilis cases have surged by nearly 80% from 2018 to 2023, with 209,253 cases recorded in the most recent year of data. Syphilis, which can be transmitted sexually or from mother... Read more
Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse
Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read moreMolecular Diagnostics
view channel
New Molecular Label to Help Develop Simpler and Faster Tuberculosis Tests
Tuberculosis (TB), the deadliest infectious disease globally, is responsible for infecting an estimated 10 million people each year and causing over 1 million deaths annually. While chest X-rays and molecular... Read more
Biomarker Discovery Paves Way for Blood Tests to Detect and Treat Osteoarthritis
The number of individuals affected by osteoarthritis is projected to exceed 1 billion by 2050. The primary risk factor for this common, often painful chronic joint condition is aging, and, like aging itself,... Read more
Liquid Biopsy Assay Detects Recurrence in CRC Patients Prior to Imaging
The detection of circulating tumor DNA (ctDNA) after treatment is a strong indicator of recurrence in colorectal cancer (CRC), but it often goes undetected due to the low traces of ctDNA present in the blood.... Read more
Ultra Fast Synovial Fluid Test Diagnoses Osteoarthritis and Rheumatoid Arthritis In 10 Minutes
Studies indicate that more than 50% of individuals aged 65 and older experience symptoms of osteoarthritis, while rheumatoid arthritis is a serious chronic condition affecting approximately 1 in 100 people... Read moreImmunology
view channel
Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more
Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
Chimeric antigen receptor (CAR) T-cell therapy has emerged as one of the most promising recent developments in the treatment of blood cancers. However, over half of non-Hodgkin lymphoma (NHL) patients... Read moreMicrobiology
view channel
New Test Diagnoses Bacterial Meningitis Quickly and Accurately
Bacterial meningitis is a potentially fatal condition, with one in six patients dying and half of the survivors experiencing lasting symptoms. Therefore, rapid diagnosis and treatment are critical.... Read more
Handheld Device Delivers Low-Cost TB Results in Less Than One Hour
Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more
New AI-Based Method Improves Diagnosis of Drug-Resistant Infections
Drug-resistant infections, particularly those caused by deadly bacteria like tuberculosis and staphylococcus, are rapidly emerging as a global health emergency. These infections are more difficult to treat,... Read more
Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours
Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read morePathology
view channel
AI-Based Liquid Biopsy Approach to Revolutionize Brain Cancer Detection
Detecting brain cancers remains extremely challenging, with many patients only receiving a diagnosis at later stages after symptoms like headaches, seizures, or cognitive issues appear. Late-stage diagnoses... Read more
AI-Driven Analysis of Digital Pathology Images to Improve Pediatric Sarcoma Subtyping
Pediatric sarcomas are rare and diverse tumors that can develop in various types of soft tissue, such as muscle, tendons, fat, blood or lymphatic vessels, nerves, or the tissue surrounding joints.... Read more
AI-Based Model Predicts Kidney Cancer Therapy Response
Each year, nearly 435,000 individuals are diagnosed with clear cell renal cell carcinoma (ccRCC), making it the most prevalent subtype of kidney cancer. When the disease spreads, anti-angiogenic therapies... Read more
Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation
Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read moreTechnology
view channel
Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses
Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more
Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples
As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more
Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more
Innovative, Label-Free Ratiometric Fluorosensor Enables More Sensitive Viral RNA Detection
Viruses present a major global health risk, as demonstrated by recent pandemics, making early detection and identification essential for preventing new outbreaks. While traditional detection methods are... Read moreIndustry
view channel
Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
Grifols (Barcelona, Spain), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, is expanding its offer in clinical diagnostics through a strategic partnership... Read more